Quarterly ResultMay 12, 2026, 04:19 PM
Zentalis Q1 Net Loss Narrows to $35.35M; R&D Expenses Up 5.4%
AI Summary
Zentalis Pharmaceuticals reported a net loss of $35.35 million for the first quarter of 2026, a significant improvement from the $48.28 million net loss in the same period last year, primarily due to the absence of restructuring charges. Research and development expenses increased by 5.4% to $28.72 million, reflecting continued investment in its lead product candidate, azenosertib. The company ended the quarter with $211.8 million in cash, cash equivalents, and marketable securities, but noted it will require substantial additional capital to fund its operations.
Key Highlights
- Net loss narrowed to $35.35 million in Q1 2026 from $48.28 million in Q1 2025.
- Net loss per common share was $(0.50) in Q1 2026, down from $(0.67) in Q1 2025.
- Research and development expenses increased 5.4% to $28.72 million in Q1 2026.
- General and administrative expenses decreased 13.6% to $9.14 million in Q1 2026.
- No restructuring charges were incurred in Q1 2026, compared to $7.80 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $211.8 million as of March 31, 2026.
- Accumulated deficit reached $1.2 billion as of March 31, 2026.
- Company expects to require substantial additional capital to finance operations.
Price Impact
More from ZNTL